Arora Natasha P, Ghali Jalal K
Division of Cardiovascular Services, Saint John Hospital and Medical Center, 22101 Moross Road, Detroit, MI 48236, USA.
Division of Cardiology, School of Medicine, Mercer University, 707 Pine Street, Macon, GA 31201, USA.
Heart Fail Clin. 2014 Apr;10(2):281-94. doi: 10.1016/j.hfc.2013.11.002.
Anemia is a common comorbidity in patients with heart failure (HF) and is associated with poor prognosis. Iron deficiency, with or without anemia, confers increased risk of mortality and morbidity. Along with the altered iron metabolism in HF patients, inflammation creates challenges in the interpretation of laboratory parameters used to diagnose anemia in HF. Since the RED-HF trial failed to demonstrate any benefit from the use of erythropoiesis-stimulating agents (ESAs) on mortality or morbidity in HF patients, ESAs are no longer considered a treatment option, although intravenous iron has potential as therapy for anemic and nonanemic HF patients.
贫血是心力衰竭（HF）患者常见的合并症，且与预后不良相关。无论是否伴有贫血，缺铁都会增加死亡和发病风险。随着HF患者铁代谢的改变，炎症给用于诊断HF患者贫血的实验室参数解读带来了挑战。由于RED-HF试验未能证明使用促红细胞生成素（ESA）对HF患者的死亡率或发病率有任何益处，尽管静脉铁剂对贫血和非贫血HF患者有治疗潜力，但ESA不再被视为一种治疗选择。
